These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial. Kawahara N, Kawaguchi R, Yamamoto K, Nishikawa K, Matsuoka M, Maehana T, Fukui Y, Yamanaka S, Sugimoto S, Iwai K, Yamada Y, Kurakami H, Hirata T, Takashima R, Suzuki S, Asada K, Kasahara M, Kimura F. Trials; 2024 Jan 19; 25(1):68. PubMed ID: 38243317 [Abstract] [Full Text] [Related]
11. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study). Kitade M, Kumakiri J, Kobori H, Murakami K. Trials; 2024 May 24; 25(1):343. PubMed ID: 38790029 [Abstract] [Full Text] [Related]
12. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. BMC Womens Health; 2021 Jun 21; 21(1):250. PubMed ID: 34154590 [Abstract] [Full Text] [Related]
16. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Fertil Steril; 2021 Feb 21; 115(2):397-405. PubMed ID: 32912633 [Abstract] [Full Text] [Related]
17. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y, Mathur V, Warsi QA, Wagman RB, Johnson NP. Lancet; 2022 Jun 18; 399(10343):2267-2279. PubMed ID: 35717987 [Abstract] [Full Text] [Related]